Antipsychotic-associated mental side effects and their relationship to dopamine D 2 receptor occupancy in striatal subdivisions: A high-resolution PET study with [ 11C]raclopride

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 507-511

  Kim, Jong Hoon ^a   Son, Young Don ^b   Kim, Hang Keun ^b   Lee, Sang Yoon ^b   Cho, Seo Eun ^a   Kim, Young Bo ^b   Cho, Zang Hee ^b  

^a Gil Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

antipsychotics; high resolution PET; mental side effects; striatal subdivisions

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE C 11; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CARBON RADIOISOTOPES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; YOUNG ADULT;

EID: 79960597504     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318222353a     Document Type: Article

References (32)

1. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl. 2005;427:43-46. (Pubitemid 40780199)
2. Voruganti LP, Awad AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand Suppl. 2005;427:22-28. (Pubitemid 40780196)
3. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88. (Pubitemid 32510889)
4. Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci. 2001;26:131-136. (Pubitemid 32373126)
5. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
6. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005;20:15-27. (Pubitemid 40092387)
7. Nordström AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235. (Pubitemid 23091497)
8. Haber SN, Kim KS, Mailly P, et al. Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci. 2006;26:8368-8376. (Pubitemid 44309851)
9. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160:13-23. (Pubitemid 36042420)
10. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007;164:630-637. (Pubitemid 46650195)
11. de Haan L, van Bruggen M, Lavalaye J, et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160:303-309. (Pubitemid 41110456)
12. de Haan L, Lavalaye J, Linszen D, et al. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019-1020. (Pubitemid 30412360)
13. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2)receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21:1034-1057. (Pubitemid 32823740)
14. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285-300. (Pubitemid 36307573)
15. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231-239.
16. Owens DGC. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge, UK: Cambridge University Press; 1999.
17. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders Research Version (SCID-I). New York, NY: New York State Psychiatric Institute, Biometric Research; 1996.
18. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry. 1990;47:213-219. (Pubitemid 20086672)
19. Hietala J, Syvälahti E, Vuorio K, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry. 1994;51:116-123. (Pubitemid 24054313)
20. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650-653.
21. Barbui C, Nosè M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25:521-526. (Pubitemid 41669042)
22. Lambert TJ, Cock N, Alcock SJ, et al. Measurement of antipsychotic- induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol. 2003;18:405-411. (Pubitemid 36896427)
23. Jung HY, Kim JH, Ahn YM, et al. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Hum Psychopharmacol. 2005;20:41-45.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
25. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
26. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
27. Fei X, Mock BH, DeGrado TR, et al. An improved synthesis of PET dopamine D2 receptors radioligand [11C]raclopride. Synth Commun. 2004;34:1897-1907. (Pubitemid 38738401)
28. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
29. Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience. 2000;96:451-474. (Pubitemid 30136312)
30. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998;155:761-767. (Pubitemid 28252654)
31. Caligiuri MP, Brown GG, Meloy MJ, et al. A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder. Bipolar Disord. 2004;6:183-196. (Pubitemid 38702294)
32. McNamara P, Stavitsky K, Harris E, et al. Mood, side of motor symptom onset and pain complaints in Parkinson's disease. Int J Geriatr Psychiatry. 2010;25:519-524.